Background: The role of home parenteral nutrition (HPN) in incurable cachectic cancer patients unable to eat is extremely controversial. The aim of this study is to analyse which factors can influence the outcome.
introduction
The indication for home parenteral nutrition (HPN) in incurable patients who are unable to eat, mainly for malignant obstruction, is extremely controversial and its use in Europe is considerably different from one country to another, accounting for 60% of all patients' population on HPN in the Netherlands and Italy to only 5% in the UK, while the remaining European countries are in between [1] . This is not unexpected because a variety of cultural factors, traditions, religious beliefs, local preferences, as well as a multitude of other social and economic factors influence decision making in nutrition for both healthy and ill people [2] .
Some authors, following a simple logic of cost/effectiveness ratio, do not recommend HPN because, while most of patients with benign intestinal failure can survive many years 'thanks' to HPN, most of patients with malignant obstruction die within weeks or months 'despite' HPN. On the contrary, others argue that some of these cancer patients actually die 'with' the tumour but not 'because' of the tumour, but because of starvation. In fact, some selected studies of incurable cancer patients receiving HPN because of malignant (sub)obstruction report a median survival of 5-6 months or more, which is longer than the usual survival time after total macronutrient deprivation (∼2-2.5 months for healthy people) (references in [3] ). These patients, if not nutritionally supported, would obviously die due to undernutrition rather than to tumour progression.
Few studies (and none prospectively) have reported that Karnofsky Performance Status (KPS), level of serum albumin and of serum cholinesterase are prognostically significant (references in [3] ); however, these scattered data proved unsuitable to guide the clinician in the recommendation of HPN. As a consequence, the European [4] and American [5] guidelines on HPN are also quite vague on this issue.
Rather than assuming a dogmatic position when facing this dilemma, we felt that a prospective investigation aimed to define if some patient-or tumour-related characteristics are associated with survival length, would be worthwhile.
patients and methods

study design and patients
The idea of investigating which factors may be significantly associated with the survival of incurable cancer patients receiving HPN was originally conceived within the Home Artificial Nutrition Working Group (HANWG) of the European Society for Clinical Nutrition and Metabolism. A prospective protocol was approved by the members of the HANWG and distributed to Centres potentially involved in HPN programmes in cancer patients. On each patient's discharge, participating centres were asked to fill up an ad hoc form including the following data: demographic, nutritional [usual and current body weight, body mass index (BMI)], clinical-oncological (life expectancy, KPS, site of primary, histopathology, tumour spread and vital organ involvement, previous oncologic treatments), biochemical variables [blood cell count, serum albumin, C-reactive protein (CRP)], indications for HPN, start date, end date and method of HPN administration and management and date of death. Furthermore, centres were required to provide additional information concerning major complications, HPN withdrawal and likely cause of death (HPN-related, organ failure or progressive wasting). For all surviving patients, it was required a minimum period of observation of at least 6 months. Body weight loss and the Glasgow Prognostic Score (GPS) were then calculated.
Centres recommended HPN according to individual institutional policies without any interference by HANWG responsible for the protocol, in compliance with the purposes of an observational study.
The patient admission criteria were the following: adults/elderly patients with no or negligible oral/enteral nutrition (usually because of intestinal obstruction/sub-obstruction, diagnosed on clinical/radiological ground and refractory to previous medical care), presence of an incurable malignancy, without major organ failure or major involvement of a vital organ or severe metabolic derangement. In addition, patients with ascites or pleural effusion (which might be exacerbated by the fluid infusion) and those with uncontrolled symptoms or those receiving HPN in the perspective to become candidate to a future oncologic treatment were excluded. It was required the prescription of an i.v. nutritional daily regimen including at least 25 kcal and 1 g amino acid/kg bodyweight. Each centre was granted permission to take part to the study from its own local Human Investigations Committee.
statistical analysis
Descriptive analyses were based on standard statistics such as relative frequencies for categorical variables (gender, age class, tumour site, tumour spread, main extent of disease, vital organ involvement, most recent therapy, GPS) or with medians and ranges for continuous variables (age, relative weight loss, BMI, CRP, serum albumin, KPS). Relative weight loss was computed either with reference to the usual weight, or with respect to the weight measured 6 months before HPN start; the latter value was also treated as categorical towards a 10% classification cut-off.
The study end point was overall survival (OS), calculated from the date of HPN start to the date of death for any cause, with censoring at the date of last follow-up assessment in alive subjects. The minimum follow-up duration for the latter was 6 months. Survival data were summarized by computing the OS curve with the Kaplan-Meier method. However, for the sake of simplicity, statistical analyses were carried out considering survival status at 3 or 6 months as a dichotomous variable.
In order to investigate the association between distinct patient or clinical characteristics and 3-or 6-month survival, Pearson's χ 2 tests were used for univariable analyses, while logistic regression models were used for multivariable analyses. Two-sided P values below the conventional 5% threshold were considered statistically significant. Statistical analyses were carried out with the SAS package (Version 9.2, SAS Institute, Cary, NC) and R software (R Foundation for Statistical Computing, Vienna, Austria).
results
study population
Thirteen centres from 10 different countries collected information for 419 consecutive, incurable cancer patients receiving HPN during a 6-year period (between November 2004 and March 2011). Five patients were not considered for the following reasons: HPN as a part of an already planned subsequent oncologic therapy (two cases); impossible diagnostic differentiation between incurable disease and radiation enteropathy (one case); missing follow-up information (two cases). Consequently, the investigated sample included 414 patients.
Series characteristics are summarized in Table 1 . Noteworthy, patients were severely malnourished, as reflected by a median weight loss, 24% of the usual weight and 16% of the weight measured 6 months before entering into the study and a median BMI of 19.5. Median KPS was 60, median life expectancy was 3 months, more than half patients had a primary abdominal gastrointestinal tumour, (sub)obstruction occurred as indication for HPN in approximately two thirds of the cases.
Patients' age was 65 years or older in 41% of the cases, and 92% of the patients were classified as stage IV according to the SCRINIO classification of cancer cachexia [6] .
The i.v. nutritional support was continued till patient's death in the majority of cases, and withdrawn earlier in one third of them (n = 139, 33.6%) for the following reasons: pre-agonic status (n = 101, 24.4%), patient/relatives refusal (n = 29, 7.0%); onset of HPN-catheter-related complications (n = 9, 2.2%). For these 139 patients, median survival time after HPN discontinuation was 2 months (range 1-126 months) overall. Median survival time was longer in the subsets of patients who discontinued HPN because of patient/relatives refusal (5 months, range 1-61) or HPN-catheter related complications (6 months, range 3-49).
survival analysis
At study conclusion, all patients except 12 (2.9%) were dead. Median survival, 3.0 months (95% confidence interval 2.7-3.3 months) in the overall series (Figure 1 ), showed little betweenoriginal articles Annals of Oncology centre variability (from 1.3 to 4.5, with widely overlapping confidence limits, when estimable).
At 3 and 6 months after HPN start, 50.0% and 22.9% patients were alive, respectively. The 3-and 6-month survival estimates were 56.9% and 27.7%, respectively, for patients without metastatic involvement of vital organs at the start of HPN, and 44.9% and 16.4%, respectively, for those with vital organ involvement.
With reference to the 143 patients (approximately one-third of the series) with the so-called refractory cachexia [7] , 3-and 6-month survival dropped to 29.4% and 8.4%. These figures were 31.7% and 12.2% for patients without vital organ involvement, 27.1% and 5.9% for those with vital organ involvement. Table 2 .
association between main factors and surviving status Number and percentage of surviving patients and P values at the univariable analyses are reported in Table 3 . Significant results were obtained for tumour spread, vital organ involvement, KPS and GPS on both end points, and for relative weight loss on 6-month survival only. However, in the multivariable analyses (Table 4) , a significant and independent prognostic effect was confirmed for KPS and GPS on 3-and 6-month survival, and for tumour spread on 6-month survival. Survival probability figures estimated for the combination of the above factors are shown in Table 5 . One may observe the substantial variability of survival figures. In particular, 3-month survival ranged from a minimum of 33% for patients with KPS ≤ 50 and GPS = 2 to a maximum of 79% for patients with KPS > 50 and GPS = 0. As regards to 6-month survival, a minimum of 6% was estimated for patients with KPS ≤ 50, GPS = 2 and extensive tumour spread, while a maximum of 61% was estimated for patients with KPS > 50, GPS = 0 and locoregional tumour spread. discussion This study involved 414 cachectic patients with an incurable malignancy receiving HPN, mainly for intestinal (sub)obstruction and without a concurrent oncologic therapy. Median relative weight loss was 24% and 92% of them had a weight loss ≥10% which means that almost all could be defined as cachectic according to two validated cancer cachexia classifications published in literature [6, 8] .
We observed a mean/median survival of 4.7/3.0 months, a finding quite similar (or a bit lower) to that of many retrospective and prospective series and in agreement with the common expectation in advanced cancer patients belonging to an area of simple palliation (references in [3] ).
The statistically significant prognostic variables were KPS, tumour spread (categorized as local-locoregional, metastatic or both) and GPS. Except for KPS, which was already reported in literature, tumour spread and GPS were never investigated before. All these indexes are simple, commonly reported in the oncologic charts, objective and can be easily quantified.
In absence of a proper control group, we cannot definitely assess which was the clinical impact of HPN. However, from a careful scrutiny of the literature (references in [3] ), we found that the survival of patients with malignant obstruction usually does not exceed 2 months if no PN support is supplied during the hospital stay and is further reduced to <2-3 weeks if patients are followed at home.
In contrast, our data showed that about 50% of the patients on HPN survived longer than what is usually observed in historical controls, and approximately one-quarter survived 6 months or longer-median survival beyond 6 months being 4.1 months. Hence, it might be that these patients benefitted from HPN in terms of longer survival. We are aware that no hard data are supporting this statement; however, parenteral nutrition of (hypo)aphagic patients is somewhat viewed as a life-saving procedure because some incurable cancer patients can survive several months [9] but the onset of aphagia drastically reduces the survival time to few weeks. In addition, a RCT to definitely set the issue would be considered unethical by many nutritionists and, on the contrary, an over-treatment by some clinicians who fear PN might only prolong and worsen symptoms of the patients.
With reference to 3-month survival, we observe that, combining information on the GPS and the KPS, distinct patients populations at higher or lower chance of survival may be discriminated (Table 5) . Similarly, the combinations of the KPS, the GPS and the pattern of tumour spread leads to 18 distinct patient groups, whose survival at 6 months ranges from only 5% to a clinically relevant 43.7% (Table 5) .
In summary, depending on the aggregation of different prognostic variables, it turns out that apparently homogeneous incurable weight-losing patients may in fact be prognostically stratified. This could help clinicians to determine HPN indication in the individual patient.
Another pivotal component of patient outcome is the quality of life. A survey [10] on the relevance of quality of life for patients with advanced cancer showed that only 22% of them would choose palliative chemotherapy, in preference to supportive care alone, to benefit from the associated 3-month additional survival advantage, in contrast, 68% would choose chemotherapy if it substantially reduced adverse symptoms without prolonging life. Since an ad hoc study [11] has shown that quality of life starts to decline in the last 2-3 months of life of these patients on HPN, this also would argue against recommending HPN in patients with a prognosis of ≤3 months. original articles
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It is noteworthy that about one-third of the patients of this series would have been considered as belonging to the 'refractory cachexia' stage by Fearon et al. [7] , yet the mean/median survival of this group was 2.8/2.1 months (3.0/2.6 months in patients without metastatic involvement of vital organs) that means that a small percentage of them could have benefitted from HPN. This argues against the recommendations of these authors who would deny HPN to all these patients and calls for the need of revising current cancer cachexia classifications.
This study has some limitations: since patients died at home, we cannot be sure about the causes of death even if the protocol specified the classification criteria. Moreover, we lack enough information about the possible weaning from HPN in the last days before death and about the exact composition of the nutritional bags and whether these complied with ESPEN recommendations [4] which suggest a relatively high fat to carbohydrate ratio and a high protein load.
In conclusion, our data show that there is a substantial variability in the survival of incurable cachectic patients on HPN, and that such variability is partly explained on the basis of few and simple prognostic factors which may be taken into account In such cases, we state as important that health professionals, recognizing that feeding is a fundamental element in human relationships and culture, approach these decisions with a special sensitivity for concerns about starvation and abandonment and families' desire to provide love and care. 
